β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10870672B2 · kind B2 · utility
3Cited by
176References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2020 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Jun 12, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.